Status:

TERMINATED

Klotho Gene Polymorphism in Dialyzed Patients With Hyperphosphatemia

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Collaborating Sponsors:

Institut National de la Santé Et de la Recherche Médicale, France

Conditions:

Chronic Kidney Disease

End Stage Renal Disease

Eligibility:

All Genders

18-80 years

Brief Summary

Patients with chronic kidney disease (CKD) and those with end-stage renal disease (ESRD) undergoing renal replacement therapies show elevated serum phosphate levels which predispose them to cardiovasc...

Detailed Description

The entire coding region of the klotho gene will be sequenced looking for functional variants and polymorphisms that differentiate two groups of adult dialyzed ESRD patients, matched for age and gende...

Eligibility Criteria

Inclusion

  • Group 1
  • Stable hemodialysis patients for at least 3 months
  • Phosphatemia \> 2.5 mM
  • Kt/V \> 1.2
  • Total weekly phosphate removal \> 75 millimoles
  • Group 2
  • Stable hemodialysis patients for at least 3 months
  • Phosphatemia \< 1.5 mM
  • Kt/V \> 1.2
  • Total weekly phosphate removal \> 25 millimoles

Exclusion

  • Age \> 80 years
  • Insufficient dialysis dose (Kt/V \< 1.2)
  • Total weekly phosphate removal \< 25 mM
  • Problems with vascular access for hemodialysis (central catheter, arteriovenous \[A-V\] fistula dysfunction)
  • Methods of dialysis different than the classical hemodialysis (peritoneal, hemofiltration, or hemodiafiltration with or without acetate)
  • Intolerance or allergy to ARYLANE M9 dialyzers
  • Hypocalcemia \< 2.0 mmol/liter
  • Hypophosphatemia \< 0.6 mmol/liter
  • Daily protein intake \< 0.6 g/kg/j
  • Parathyroidectomy at least 3 months prior to the study
  • Evolutive neoplasia with or without secondary lytic bone lesions
  • Intestinal malabsorption
  • Alcoholism
  • Corticotherapy
  • Treatment by bisphosphonates, fluor or recombinant PTH
  • Malnutrition (body mass index \[BMI\] \< 15)
  • Amputation of lower members (\> 10% of total body)
  • Prolonged immobilization
  • Secondary hyperparathyroidism (PTH \> 1400 pg/ml)
  • Vitamin D deficiency (25OHD3 \< 10 ng/ml)

Key Trial Info

Start Date :

January 1 2005

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

November 1 2007

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT00374712

Start Date

January 1 2005

End Date

November 1 2007

Last Update

November 8 2007

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Clinique de l'Orangerie - Service de Néphrologie et Dialyse

Aubervilliers, France, 93300